Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers

Title
Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers
Authors
Vasilios Tsouris주민경김선화권익찬원유연
Keywords
Cancer; Drug resistance; Chemotherapy; RNA interference; Combination therapy; Co-delivery
Issue Date
2014-09
Publisher
Biotechnology advances
Citation
VOL 32, 1037-1050
Abstract
Tumor cells exhibit drug resistant phenotypes that decrease the efficacy of chemotherapeutic treatments. The drug resistance has a genetic basis that is caused by an abnormal gene expression. There are several types of drug resistance: efflux pumps reducing the cellular concentration of the drug, alterations in membrane lipids that reduce cellular uptake, increased or altered drug targets,metabolic alteration of the drug, inhibition of apoptosis, repair of the damaged DNA, and alteration of the cell cycle checkpoints (Gottesman et al., 2002; Holohan et al., 2013). siRNA is used to silence the drug resistant phenotype and prevent this drug resistance response. Of the listed types of drug resistance, pump-type resistance (e.g., high expression of ATP-binding cassette transporter proteins such as P-glycoproteins (Pgp; also known asmulti-drug resistance protein 1 orMDR1, encoded by the ATP-Binding Cassette Sub-Family B Member 1 (ABCB1) gene)) and apoptosis inhibition (e.g., expression of antiapoptotic proteins such as Bcl-2) are the most frequently targeted for gene silencing. The co-delivery of siRNA and chemotherapeutic drugs has a synergistic effect, butmany of the current projects do not control the drug release fromthe nanocarrier. This means that the drug payload is released before the drug resistance proteins have degraded and the drug resistance phenotype has been silenced. Current research focuses on cross-linking the carrier's polymers to prevent premature drug release, but these carriers still rely on environmental cues to release the drug payload, and the drugmay be released too early. In this review, we studied the release kinetics of siRNA and chemotherapeutic drugs from a broad range of carriers.We also give examples of carriers used to co-deliver siRNA and drugs to drug-resistant tumor cells, and we examine howmodifications to the carrier affect the delivery. Lastly, we give our recommend
URI
https://pubs.kist.re.kr/handle/201004/48739
ISSN
07349750
Appears in Collections:
KIST Publication > Article
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE